Oncology

 

Oncology

Measuring Biomarkers
at Every Stage
of Tumor Development

The ability to detect oncology biomarkers at ultra-low levels has the potential to enable new options for diagnostics and treatment in cancer research.

Simoa assays have the potential to be used to monitor cancer risk, identify early stage cancers and discriminate between benign and malignant cells. Simoa biomarkers also have the potential to be used prognostically to predict disease outcome, predict progression free survival and monitor reoccurrence, and to be used to monitor sensitivity to therapy and to aid in treatment decisions.

Latest News

09.06
In this study, we investigated the molecular mechanisms dictating the interactions between human MAIT cells and DCs and demonstrate that human MAIT cells mature monocyte-derived and primary DCs in an MR1- and CD40L-dependent manner.